Mechanism of Enhancing Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma
Research Report on Enhancing Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma with Paricalcitol and Hydroxychloroquine Background Pancreatic Ductal Adenocarcinoma (PDAC) has an extremely low survival rate, with a 5-year survival rate of less than 15%. The primary reasons are early tumor metastasis and high resistance to chemotherapy and ra...